5-Ethyl-1-(4-hydroxy-benzyl)-2-phenylethynyl-7-((R)-phenylmethyl)-7,8-dihydro-1H,5H-imidazo[2,1-b]purin-4-one

ID: ALA362938

Chembl Id: CHEMBL362938

PubChem CID: 44402168

Max Phase: Preclinical

Molecular Formula: C31H27N5O2

Molecular Weight: 501.59

Molecule Type: Small molecule

Associated Items:

Names and Identifiers

Canonical SMILES:  CCN1C(=O)c2nc(C#Cc3ccccc3)n(Cc3ccc(O)cc3)c2N2C[C@@H](Cc3ccccc3)N=C12

Standard InChI:  InChI=1S/C31H27N5O2/c1-2-34-30(38)28-29(36-21-25(32-31(34)36)19-23-11-7-4-8-12-23)35(20-24-13-16-26(37)17-14-24)27(33-28)18-15-22-9-5-3-6-10-22/h3-14,16-17,25,37H,2,19-21H2,1H3/t25-/m1/s1

Standard InChI Key:  HDSXUCHBXDIWDC-RUZDIDTESA-N

Associated Targets(Human)

PDE5A Tclin Phosphodiesterase 5A (5113 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
PDE5A Tclin Phosphodiesterase, PDE1/PDE5 (107 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
PDE5A Tclin Phosphodiesterases; PDE5 & PDE6 (103 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 501.59Molecular Weight (Monoisotopic): 501.2165AlogP: 4.30#Rotatable Bonds: 5
Polar Surface Area: 73.96Molecular Species: NEUTRALHBA: 6HBD: 1
#RO5 Violations: 1HBA (Lipinski): 7HBD (Lipinski): 1#RO5 Violations (Lipinski): 1
CX Acidic pKa: 10.20CX Basic pKa: 2.33CX LogP: 6.14CX LogD: 6.14
Aromatic Rings: 4Heavy Atoms: 38QED Weighted: 0.41Np Likeness Score: -0.50

References

1. Boyle CD, Xu R, Asberom T, Chackalamannil S, Clader JW, Greenlee WJ, Guzik H, Hu Y, Hu Z, Lankin CM, Pissarnitski DA, Stamford AW, Wang Y, Skell J, Kurowski S, Vemulapalli S, Palamanda J, Chintala M, Wu P, Myers J, Wang P..  (2005)  Optimization of purine based PDE1/PDE5 inhibitors to a potent and selective PDE5 inhibitor for the treatment of male ED.,  15  (9): [PMID:15837326] [10.1016/j.bmcl.2005.02.083]

Source